Study details
Enrolling now
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
University of Washington
NCT IDNCT05183828ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
68
Study length
about 3.9 years
Ages
18+
Sex
Female only
Locations
1 site in WA
What this study is about
This trial is testing how a mutation in the HSD3B1 gene affects treatment for stage I-III breast cancer. It may help researchers determine if mutations in HSD3B1 decrease the effectiveness of aromatase inhibitor therapy, such as letrozole.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Questionnaire Administration
- 2.Take Letrozole
- 3.Undergo Biospecimen Collection
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
letrozole (Aromatase inhibitor; prevents estrogen production)
Drug routes
oral
Procedures
diagnostic
Body systems
Oncology